Wednesday, 12 Dec 2018

You are here

Recurrent Uveitis Increases the Risk of Ankylosing Spondylitis

Arthritis Research and Therapy reports on the epidemiologic association between recurrent anterior uveitis and ankylosing spondylitis (AS) noting that as the number of uveitis episodes increases, so does the incidence of AS.

Uveitis is the most common extra-articular manifestation of AS, occurring in up to 40% of AS patients. As such AS-related anterior uveitis may first present to the ophthalmologist, not by a rheumatologist.  These investigators asked the question - how oftent does recurrent anterior uveitis result in subsequent AS. 

A national cohort of10,483 patients with new-onset uveitis (seen between 2004 -2013) was compared to 52415 matched control subjects (never had uveitis).

After the first uveitis episode, the AS risk was 7 fold higher (incidence rate ratio = 7.4 compared to normal controls).

After the the second uveitis episode, the IRR further increased to 17.71.  High rates of AS were seen in both male and female patients with recurrent uveitis (IRR 284.1 and 268.7 per 100,000 person-years, respectively.

As disease controls, patients with RA or herniatiated vertebral discs did not show a correlation with the occurrence or recurrence of uveitis.

The risk of subsequent AS increased with the number of episodes of anterior uveitis. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

New ACR/NPF Guidelines for Management of Psoriatic Arthritis

The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA) that provides evidence-based pharmacologic and non-pharmacologic recommendations and includes recommendations on other management issues including vaccinations, psoriatic spondylitis, enthesitis, and treatment in the presence of inflammatory bowel disease, diabetes, or serious infections.

Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis

Another, new Janus kinase 1 (JAK1) inhibitor is out with impressive data - this time its filgotinib, demonstrating its efficacy and safety two separate clinical trials of patients with psoriatic arthritis or ankylosing spondylitis.

Ixekizumab COAST-V Trial Wins in Axial Spondyloarthritis

Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).

Doubling Down on IL-17 In Psoriatic Arthritis

The monoclonal antibody bimekizumab, which neutralizes both interleukin (IL)-17A and 17F, was effective for both musculoskeletal and skin outcomes in psoriatic arthritis (PsA) in a phase IIb study.

Updates on Psoriatic Arthritis at ACR 2018

I think 2018 was the year that belonged to psoriatic arthritis (although some may argue in favor of immune conditions induced by Checkpoint inhibitors). Many years ago the late Professor Verna Wright in Leeds (UK) was a lone voice for many years describing the clinical subtypes of Psoriatic arthritis as something distinctive from rheumatoid arthritis. For a long time we thought that the treatments for PsA were just the same as RA since we were treating the same problem of synovitis.